Cost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data
GAAD, alone or combined with US, is a cost-effective strategy for HCC surveillance in CC patients in Italy, improving the detection of early-stage disease. Better performance data for US+GAAD is needed to confirm results.
Authors
- Maria Teresa Majorini (ORCID: https://orcid.org/0000-0001-5903-3657)
- Vincenza Calvaruso (ORCID: https://orcid.org/0000-0002-0287-1059)
- Camilla Porta (ORCID: https://orcid.org/0000-0001-8402-6934)
- Osvaldo Ulises Garay
- Lucia Napoli
- Tommaso FASANO
- Giovanni Cirotto
- Pietro Lampertico
- Francesco Giuseppe Foschi
Institutions
- Roche (Switzerland) (CH)
- Ospedale Maggiore (IT)
- Azienda Unita' Sanitaria Locale Di Modena (IT)
- Department of Health (ES)
- Center for Digestive and Liver Diseases (US)
- Ospedale per gli Infermi (IT)
- Adresseavisen (Norway) (NO)
- CS Diagnostics (DE)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1080/13696998.2026.2627833
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00